HRP20040112B1 - Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof - Google Patents

Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Info

Publication number: HRP20040112B1
Authority: HR; Croatia
Prior art keywords: acid salt; ylidene; carboxamide; diethylamino; indole
Prior art date: 2001-08-15

Application number

HR20040112A

Other languages

English (en)

Croatian (hr)

Inventor

Hawley Michael

J. Fleck Thomas

P. Prescott Stephen

T. Maloney Mark

Original Assignee

Pharmacia & Upjohn Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-15

Filing date

2002-08-13

Publication date

2012-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040112(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-13 Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company

2004-06-30 Publication of HRP20040112A2 publication Critical patent/HRP20040112A2/hr

2012-03-31 Publication of HRP20040112B1 publication Critical patent/HRP20040112B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Obesity (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

HR20040112A 2001-08-15 2002-08-13 Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof HRP20040112B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31235301P	2001-08-15	2001-08-15
PCT/US2002/025649 WO2003016305A1 (en)	2001-08-15	2002-08-13	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (2)

Publication Number	Publication Date
HRP20040112A2 HRP20040112A2 (en)	2004-06-30
HRP20040112B1 true HRP20040112B1 (en)	2012-03-31

Family

ID=23211067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20040112A HRP20040112B1 (en)	2001-08-15	2002-08-13	Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Country Status (42)

Country	Link
US (2)	US20030069298A1 (bg)
EP (3)	EP2332934B1 (bg)
JP (1)	JP4159988B2 (bg)
KR (1)	KR100639281B1 (bg)
CN (2)	CN100439360C (bg)
AP (1)	AP1660A (bg)
AR (1)	AR036261A1 (bg)
AU (1)	AU2002324684B2 (bg)
BG (1)	BG108553A (bg)
BR (1)	BR0211612A (bg)
CA (1)	CA2455050C (bg)
CO (1)	CO5550431A2 (bg)
CU (1)	CU23713B7 (bg)
CY (1)	CY1121552T1 (bg)
CZ (1)	CZ2004196A3 (bg)
DK (2)	DK3168218T3 (bg)
EA (1)	EA006445B9 (bg)
EC (1)	ECSP044975A (bg)
ES (3)	ES2453164T3 (bg)
GE (1)	GEP20063777B (bg)
HR (1)	HRP20040112B1 (bg)
HU (1)	HU229206B1 (bg)
IL (1)	IL160097A0 (bg)
IS (1)	IS7147A (bg)
MA (1)	MA27058A1 (bg)
ME (1)	ME00414B (bg)
MX (1)	MXPA04001452A (bg)
MY (1)	MY139383A (bg)
NO (1)	NO326508B1 (bg)
NZ (1)	NZ531232A (bg)
OA (1)	OA12650A (bg)
PL (1)	PL216524B1 (bg)
PT (2)	PT3168218T (bg)
RS (1)	RS53251B (bg)
SI (2)	SI1419151T1 (bg)
SK (1)	SK902004A3 (bg)
TN (1)	TNSN04028A1 (bg)
TR (1)	TR201900509T4 (bg)
TW (1)	TWI269796B (bg)
UA (1)	UA76483C2 (bg)
WO (1)	WO2003016305A1 (bg)
ZA (1)	ZA200400706B (bg)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2332934B1 (en)	2001-08-15	2017-03-01	Pharmacia & Upjohn Company LLC	Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
HN2003000272A (es) *	2002-09-10	2008-07-29	Pharmacia Italia Spa	Formulaciones que comprenden un compuesto de indolinona
BRPI0415022A (pt) *	2003-10-02	2006-11-28	Pharmacia & Upjohn Co Llc	sais e polimorfos de um composto de indolinona substituìda com pirrol
US20060009510A1 (en) *	2004-07-09	2006-01-12	Pharmacia & Upjohn Company Llc	Method of synthesizing indolinone compounds
DK1773811T3 (da) *	2004-07-22	2010-12-13	Lilly Co Eli	Krystallinsk variabelt hydrat af (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amin)-2-methylpropyl)phenoxy)-3-pyridincarboxamid-hemisuccinatsalt
CA2603445A1 (en) *	2005-05-12	2006-11-16	Pfizer Inc.	Anticancer combination therapy using sunitinib malate
AU2006293644B2 (en)	2005-09-19	2012-05-31	Zoetis Services Llc	Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
US20100256392A1 (en) *	2007-11-21	2010-10-07	Teva Pharmaceutical Industries Ltd.	Polymorphs of sunitinib base and processes for preparation thereof
EP2220072A2 (en) *	2007-11-21	2010-08-25	Teva Pharmaceutical Industries Ltd.	Polymorphs of sunitinib base and processes for preparation thereof
US8389562B2 (en) *	2007-12-12	2013-03-05	Medichem, S.A.	Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en)	2008-02-13	2009-08-19	Ratiopharm GmbH	Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en)	2008-04-29	2009-11-04	Ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
CA2715657A1 (en) *	2008-02-21	2009-08-27	Generics (Uk) Limited	Novel polymorphs and processes for their preparation
EP2098521A1 (en) *	2008-03-06	2009-09-09	Ratiopharm GmbH	Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
JP2011516488A (ja) *	2008-03-31	2011-05-26	テバファーマシューティカルインダストリーズリミティド	スニチニブ及びその塩の調製方法
WO2009128083A1 (en) *	2008-04-16	2009-10-22	Natco Pharma Limited	Novel polymorphic forms of sunitinib base
WO2009140928A1 (zh)	2008-05-23	2009-11-26	上海医药工业研究院	二氢吲哚酮衍生物
AR072117A1 (es) *	2008-06-13	2010-08-04	Medichem Sa	Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en)	2008-06-24	2009-12-30	ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) *	2008-06-26	2009-12-30	Medichem, S.A.	Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
JP2011527330A (ja) *	2008-07-10	2011-10-27	ジェネリクス・（ユーケー）・リミテッド	スニチニブリンゴ酸塩の結晶形の調製方法
KR20110036588A (ko)	2008-07-24	2011-04-07	테바 파마슈티컬 인더스트리즈 리미티드	수니티닙 아세테이트 및 이의 다형을 통한 수니티닙 말레이트의 제조 방법
WO2010010454A2 (en)	2008-07-24	2010-01-28	Medichem, S.A.	Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
CA2734965A1 (en) *	2008-08-25	2010-03-04	Generics [Uk] Limited	Novel crystalline form and processes for its preparation
CN102197034A (zh) *	2008-08-25	2011-09-21	基因里克斯(英国)有限公司	舒尼替尼的新型多晶型物及其制备方法
CN102177155A (zh) *	2008-10-10	2011-09-07	麦迪凯姆股份公司	一种3-吡咯取代的2-吲哚酮苹果酸盐的制备工艺
EP2181991A1 (en) *	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Novel salts of sunitinib
EP2186809A1 (en)	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	New crystal form of sunitinib malate
EP2896618A1 (en) *	2009-01-02	2015-07-22	Hetero Research Foundation	Polymorphs of sunitinib malate
TWI447108B (zh)	2009-01-16	2014-08-01	Exelixis Inc	Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
EP2255792A1 (en)	2009-05-20	2010-12-01	Ratiopharm GmbH	Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en)	2009-07-10	2011-01-13	Generics [Uk] Limited	Novel pyrrole derivatives
US20120220783A1 (en)	2009-09-16	2012-08-30	Ranbaxy Laboratories Limited	Salts of sunitinib
WO2011058521A2 (en) *	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en)	2009-11-19	2014-12-23	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en)	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en)	2010-02-09	2011-08-18	Sicor Inc.	Polymorphs of sunitinib salts
WO2011104555A2 (en)	2010-02-25	2011-09-01	Generics [Uk] Limited	Novel process
CA2792039A1 (en)	2010-03-04	2011-09-09	Ranbaxy Laboratories Limited	Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en)	2010-03-18	2011-09-22	Ranbaxy Laboratories Limited	Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en)	2010-04-16	2011-10-20	Generics [Uk] Limited	Novel process
WO2012042421A1 (en)	2010-09-29	2012-04-05	Pfizer Inc.	Method of treating abnormal cell growth
CA3019531A1 (en)	2011-04-19	2012-10-26	Pfizer Inc.	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2013140232A1 (en)	2012-03-23	2013-09-26	Laurus Labs Private Limited	An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl)	2012-04-27	2013-10-28	Instytut Farmaceutyczny	Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
EP2844282B1 (en)	2012-05-04	2019-06-12	Pfizer Inc	Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en)	2013-10-18	2016-03-08	Sun Pharmaceutical Industries Limited	Ascorbic acid salt of sunitinib
CA2838587A1 (en) *	2013-10-18	2015-04-18	Hari Babu Matta	Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
DK3062815T3 (en)	2013-11-01	2019-03-11	Pfizer	Vectors for expression of prostate-associated antigens
CN104693187A (zh) *	2013-12-10	2015-06-10	安杰世纪生物科技（北京）有限公司	一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) *	2013-12-25	2019-05-28	江苏豪森药业集团有限公司	苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) *	2014-10-01	2015-11-10	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) *	2014-12-05	2016-06-29	广州白云山医药集团股份有限公司白云山制药总厂	一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en)	2018-03-15	2019-09-18	MH10 Spolka z ograniczona odpowiedzialnoscia	A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en)	2019-04-25	2020-10-29	Synthon B.V.	Pharmaceutical composition comprising amorphous sunitinib
JP2022529290A (ja) *	2019-04-18	2022-06-20	メーターヘルスインコーポレイテッド	呼吸性不整脈を処置するための方法および組成物
JP7633786B2 (ja)	2020-09-18	2025-02-20	日本化薬株式会社	スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko)	2022-08-19	2024-02-27	주식회사 스카이테라퓨틱스	무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001037820A2 (en) *	1999-11-24	2001-05-31	Sugen, Inc.	Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) *	2000-02-15	2001-08-23	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE157361T1 (de)	1990-10-15	1997-09-15	Pfizer	Indolderivate
IL100091A (en)	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
CZ282060B6 (cs)	1992-06-05	1997-05-14	Merck Sharp And Dohme Limited	Sulfátová sůl substituovaného triazolu, způsob její výroby, farmaceutický prostředek s jejím obsahem a způsob jeho výroby
ZA941586B (en) *	1993-03-12	1995-09-07	Upjohn Co	Crystalline ceftiofur free acid
US6329364B1 (en)	1994-08-31	2001-12-11	Eli Lilly And Company	Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de)	1995-02-07	1998-07-02	Mack Chem Pharm	Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) *	1995-05-30	1997-01-28	Motorola, Inc.	Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) *	1995-07-06	1997-10-07	Moore; James R.	Instructional toothbrush
US20020038021A1 (en)	1995-12-11	2002-03-28	Barton Kathleen P.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en)	1995-12-11	2002-04-18	Barton Kathleen P.	Eplerenone crystalline form
US6066647A (en)	1996-07-29	2000-05-23	Pfizer Inc.	Zwitterionic forms of trovafloxacin
JP3631763B2 (ja)	1996-08-14	2005-03-23	ジー・ディー・サール・アンド・カンパニー	４―［５―メチル―３―フェニルイソキサゾル―４―イル］ベンゼンスルホンアミドの結晶形
KR100530601B1 (ko)	1996-12-25	2005-11-23	니폰 가야꾸 가부시끼가이샤	시스플라틴 미분말 및 그의 제조방법
US5777185A (en) *	1997-09-09	1998-07-07	Laroche Industries Inc.	Production of organic fluorine compounds
US6133305A (en) *	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) *	1998-01-26	2000-01-11	The Boeing Company	Galley vacuum waste disposal system
EP1956014B1 (en)	1998-06-19	2019-01-16	Teijin Pharma Limited	Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
JP2002532492A (ja) *	1998-12-17	2002-10-02	エフ．ホフマン−ラロシュアーゲー	サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US6239141B1 (en)	1999-06-04	2001-05-29	Pfizer Inc.	Trovafloxacin oral suspensions
US6316672B1 (en)	2001-01-31	2001-11-13	Grayson Walker Stowell	Form a of fluoxetine hydrochloride
EP2332934B1 (en)	2001-08-15	2017-03-01	Pharmacia & Upjohn Company LLC	Processes for the preparation of crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide.
CA2715657A1 (en)	2008-02-21	2009-08-27	Generics (Uk) Limited	Novel polymorphs and processes for their preparation
WO2009156837A2 (en)	2008-06-26	2009-12-30	Medichem, S.A.	Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

2002
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/en not_active Expired - Lifetime
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/en active IP Right Grant
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Expired - Lifetime
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 CA CA002455050A patent/CA2455050C/en not_active Expired - Lifetime
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/en not_active Expired - Lifetime
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/en not_active Expired - Lifetime
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko not_active Expired - Lifetime
- 2002-08-13 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001037820A2 (en) *	1999-11-24	2001-05-31	Sugen, Inc.	Ionizable indolinone derivatives and their use as ptk ligands
WO2001060814A2 (en) *	2000-02-15	2001-08-23	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number	Publication date
US20030069298A1 (en)	2003-04-10
ECSP044975A (es)	2004-03-23
TR201900509T4 (tr)	2019-02-21
CU23713B7 (es)	2011-10-05
EA006445B1 (ru)	2005-12-29
JP2005503386A (ja)	2005-02-03
DK3168218T3 (en)	2019-01-14
HRP20040112A2 (en)	2004-06-30
HK1088008A1 (zh)	2006-10-27
EP3168218B1 (en)	2018-11-14
NZ531232A (en)	2004-11-26
EP2332934A1 (en)	2011-06-15
CN100364991C (zh)	2008-01-30
KR20040030074A (ko)	2004-04-08
ES2623094T3 (es)	2017-07-10
NO326508B1 (no)	2008-12-15
CO5550431A2 (es)	2005-08-31
RS10304A (en)	2007-02-05
EA200400183A1 (ru)	2004-08-26
ES2705063T3 (es)	2019-03-21
EP3168218A1 (en)	2017-05-17
AP1660A (en)	2006-09-09
PL216524B1 (pl)	2014-04-30
MY139383A (en)	2009-09-30
BR0211612A (pt)	2004-08-24
US20070191458A1 (en)	2007-08-16
HK1066542A1 (en)	2005-03-24
MXPA04001452A (es)	2004-05-20
AR036261A1 (es)	2004-08-25
CN1543462A (zh)	2004-11-03
MA27058A1 (fr)	2004-12-20
SI1419151T1 (sl)	2014-04-30
PL368317A1 (en)	2005-03-21
IL160097A0 (en)	2004-06-20
CN1789264A (zh)	2006-06-21
EP1419151B1 (en)	2014-02-26
CZ2004196A3 (cs)	2005-01-12
ES2453164T3 (es)	2014-04-04
AU2002324684B2 (en)	2006-10-05
CA2455050C (en)	2007-02-20
AP2004002976A0 (en)	2004-03-31
NO20041054L (no)	2004-03-12
EP2332934B1 (en)	2017-03-01
CN100439360C (zh)	2008-12-03
CY1121552T1 (el)	2020-05-29
HU229206B1 (en)	2013-09-30
CA2455050A1 (en)	2003-02-27
PT3168218T (pt)	2019-01-11
WO2003016305A1 (en)	2003-02-27
US7435832B2 (en)	2008-10-14
ME00414B (me)	2011-10-10
HUP0700036A2 (en)	2008-10-28
PT1419151E (pt)	2014-03-27
RS53251B (sr)	2014-08-29
GEP20063777B (en)	2006-03-27
BG108553A (bg)	2005-04-30
TWI269796B (en)	2007-01-01
OA12650A (en)	2006-06-19
EA006445B9 (ru)	2017-02-28
DK1419151T3 (da)	2014-03-31
UA76483C2 (en)	2006-08-15
CU20040029A7 (es)	2008-03-14
SI3168218T1 (sl)	2019-05-31
ZA200400706B (en)	2005-05-25
EP1419151A1 (en)	2004-05-19
KR100639281B1 (ko)	2006-10-31
IS7147A (is)	2004-02-10
JP4159988B2 (ja)	2008-10-01
TNSN04028A1 (fr)	2006-06-01
SK902004A3 (sk)	2005-03-04

Publication	Publication Date	Title
HRP20040112B1 (en)	2012-03-31	Crystals including a malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
DK1470114T3 (da)	2009-11-02	Peptid-nukleinsyre-oligomerer fra 1-benzensulfonyl-3-aminosyre sidekæde-4-(2-nucleobase(acetyl))-piperazin-2-oner
PE20040644A1 (es)	2004-09-18	Nuevos derivados de quinuclidina-amina
RS51477B (en)	2011-04-30	SUBSTITUTED ALKYLAMINE DERIVATIVES AND PROCEDURES FOR THEIR USE
NO20091892L (no)	2009-06-17	Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
ATE374765T1 (de)	2007-10-15	Substituierte heterocyclische amide
BR0307060A (pt)	2004-10-26	ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
NO20050832L (no)	2005-02-16	Selektive estrogenreseptormodulatorer inneholdende en fenylsulonylgruppe
ATE316962T1 (de)	2006-02-15	Pyrimidin-derivate als selective inhibitoren von cox-2
ATE455761T1 (de)	2010-02-15	Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten
ATE240098T1 (de)	2003-05-15	Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
ATE280776T1 (de)	2004-11-15	Medizinische verwendung von mechanismus- orientierten inhibitoren der dipeptidylpeptidase i
ATE293591T1 (de)	2005-05-15	Neue n-(2-phenyl-3-aminopropyl)naphtamide
DK1584617T3 (da)	2010-05-31	Alkylpyridiniumdicyanamider som polære opløsningsmidler
WO2001030759A3 (en)	2001-09-13	Sodium-hydrogen exchanger type 1 inhibitor crystals
NO20031030D0 (no)	2003-03-05	Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel
TH66471A (th)	2005-01-17	N-ยูรีอิโดแอลคิล-พิเพอริดีนในฐานะสารปรับแอคติวิตีของคีโมไคน์รีเซปเตอร์
DE602004016331D1 (de)	2008-10-16	Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors
TH69655A (th)	2005-07-19	ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้

Legal Events

Date	Code	Title	Description
2004-06-30	A1OB	Publication of a patent application
2004-10-25	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2012-03-31	B1PR	Patent granted
2019-09-06	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20190807 Year of fee payment: 18
2020-09-04	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20200730 Year of fee payment: 19
2021-08-20	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20210811 Year of fee payment: 20
2022-08-30	PB20	Patent expired after termination of 20 years	Effective date: 20220813